Flow Pharma is a biotechnology company headquarter in San Francisco Bay Area. Founded by several famous executives Reid Rubsamen and Jack Lloyd, Flow Pharma aims to tackle one of the most difficult challenges of our time – treating cancer. Since 2009, Flow Pharma developed highly optimized vaccine delivery platform called SEAPAC, that can be used to treat, or even cure a wide variety of diseases, including viral diseases and cancer. In addition, Flow Pharma partnered with several Chinese, European and American companies and developed a highly accurate neoantigen selection system that can identify and validate the targets on cancer cells within 3 weeks, and manufacture and deliver the personalized cancer vaccine in another week.
In addition, Flow Pharma’s technology bears the most important hallmarks of a groundbreaking cancer treatment technologies: safe, effective, low cost, and broadly applicable. No other immunotherapies in the world can compete with Flow Pharma on all 4 fronts. In fact, Flow Pharma’s technology excels in every single category.
Flow Pharma’s technology has been tested on a mouse Ebola model and achieved sterling results: the vaccinated mice was protected from morbidity and mortality 100%; in comparison, 60-80% of unvaccinated mice died of the viral infection; even those that survived was severely sick for several days before recovering.
With the help from Dr. Lu Wang, Flow Pharma started a joint venture in China in 2017, Hefei Sageland Biotechnology Co Ltd. Within a year Flow Pharma accomplished several milestones : 1) In collaboration with the Chinese Academy of Medical Sciences, Flow Pharma designed two clinical protocols aiming to put a cervical cancer vaccine to test; 2) Flow Pharma received investments from Hefei Button Capital and BGI’s Miracle Light Accelerator; 3) Flow Pharma identified a companion diagnostics company and a gene sequencing company in China; 4) Flow Pharma established a manufacturing and R&D facility in Nanjing, China that’s capable of manufacturing a medical device that can prevent surgical site infection; 5) Last but least, Flow Pharma participated Shanghai Yangpu District’s Star of Startups competition and won the first place in the Silicon Valley Region.
Flow Pharma sees its work in China as an important pillar of its global operation. The company deeply appreciate China’s world-class medical facility and excellent clinical research staff and operation. In 2020 Flow Pharma will initiate a Phase II clinical trial in China, with its FlowVAX HPV cervical lesion and cervical cancer vaccine. Upon approval, this vaccine is expected to help hundreds of thousands of patients per year.
On September 14, 2019, the Flow Pharma team will personally attend the "40th anniversary celebration of the establishment of diplomatic relations between China and the United States, the 5th Outstanding Contribution Award Ceremony between the United States and China, and the China US Investment Summit Forum" and conduct on-site roadshows. Stay tuned!